Evidence map›Paper›PMID 42115154›Full record

ArticleNature communications2026

HTLV-1 subverts the innate immune effector gene IRF7 by viral HBZ protein for oncogenesis.

Xiaoyi Yuan, Yunyun Yue, Liang Chen, Dongmei Liu, Yi Liang, Chengcheng Lu, Sikai Yang, Zeng He, Chunxin Fan, Jing Shang and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiaoyi YuanState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Yunyun YueSchool of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China.
Liang ChenState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.ORCID http://orcid.org/0009-0006-6102-8500
Dongmei LiuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.ORCID http://orcid.org/0009-0002-2142-776X
Yi LiangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Chengcheng LuKey Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, Shanghai Ocean University, Shanghai, China.
Sikai YangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Zeng HeState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Chunxin FanKey Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, Shanghai Ocean University, Shanghai, China.
Jing ShangState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
Masao MatsuokaDepartment of Hematology, Rheumatology and Infectious Diseases, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID http://orcid.org/0000-0002-0473-754X
Guangyong MaState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China. gma@cpu.edu.cn.ORCID http://orcid.org/0000-0002-2003-7201

Funding

China Pharmaceutical University (CPU) 3154070031National Natural Science Foundation of China (National Science Foundation of China) 32070155National Natural Science Foundation of China (National Science Foundation of China) 32270171
6 · The paper itself

Abstract

Interferon regulatory factors (IRFs) are innate immune transcription factors responsible for inducing the expression of type I interferons (IFN-I), which combat pathogen invasions via initiating the downstream Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway. Among them, IRF7 plays a central role by forming heterodimers with IRF3 to initiate IFN-I production and is therefore frequently targeted by viruses to evade immune detection. Contrary to this common paradigm, we show that IRF7 is activated and upregulated by the retrovirus human T-cell leukemia virus type 1 (HTLV-1), via its oncoprotein HBZ. Moreover, IRF7 is highly expressed in HTLV-1 induced CD4 T-cell malignancy named adult T-cell leukemia/lymphoma (ATLL), and promotes the proliferation of infected cells both in vitro and in vivo. Intriguingly, HBZ is able to interfere with the interaction of IRF7 and IRF3, suppressing IFN-I pathway activation. On the other hand, IRF7 was found to upregulate and activate STAT5B, a transcription factor of the JAK-STAT pathway frequently mutated in hematological malignancies. Together, these findings reveal a mechanism by which HTLV-1 hijacks a critical innate immune effector to sustain persistent infection and drive oncogenesis without activating antiviral IFN-I pathway.

Indexed as

Basic-Leucine Zipper Transcription FactorsCarcinogenesisHuman T-lymphotropic virus 1Immunity, InnateInterferon Regulatory Factor-7Leukemia-Lymphoma, Adult T-CellRetroviridae ProteinsAnimalsCell Line, TumorCell ProliferationHumansInterferon Regulatory Factor-3Interferon Type IMiceSignal TransductionSTAT5 Transcription FactorBasic-Leucine Zipper Transcription FactorsHBZ protein, human T-cell leukemia virus type IInterferon Regulatory Factor-3Interferon Regulatory Factor-7Interferon Type IIRF3 protein, humanIRF7 protein, humanRetroviridae ProteinsSTAT5 Transcription Factor

Identifiers

PMID42115154
PMCPMC13376504

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.